Hypertriglyceridemia is associated with platelet hyperactivation in metabolic syndrome patients

Wang, Tingting; Xu, Jin; Li, Fu; Li, Li

doi:10.1111/ijcp.13508

Cited by 10 publications

(4 citation statements)

References 48 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Elevations in triglyceride are usually accompanied by reductions in high-density lipoprotein (HDL) cholesterol, which is thought to be cardioprotective [32], and sometimes by elevations in LDL cholesterol, an established causal risk factor for ASCVD [33]. However, recent studies suggest a direct association between HTG and ASCVD risk, even after adjusting for LDL, non-HDL and HDL cholesterol, among other covariates [31 ▪ ,34 ▪ ,35–38]. Elevated triglycerides also significantly associate with ASCVD risk in patients regardless of baseline cardiovascular risk, including patients undergoing concurrent statin therapy to control LDL cholesterol [36,37].…”

Section: Atherosclerosis and Hypertriglyceridemiamentioning

confidence: 99%

Genetics of hypertriglyceridemia and atherosclerosis

Gill

Dron

Hegele

2021

Current Opinion in Cardiology

View full text Add to dashboard Cite

Purpose of reviewThe relationship between elevated triglyceride levels (i.e. hypertriglyceridemia) and risk of atherosclerotic cardiovascular disease (ASCVD) has been investigated for decades. Recent genetic studies have sought to resolve the decades-old question of a causal relationship. Recent findingsGenetic studies seem to demonstrate associations between elevated triglyceride levels and ASCVD risk. Mendelian randomization studies suggest this association may be causal. However, simultaneous pleiotropic effects of metabolically linked lipid variables -such as non-HDL cholesterol, apolipoprotein B and HDL cholesterol -often go unaccounted for in these studies. Complex underlying pleiotropic interactions of triglycerides with these lipid fractions together with unmeasured intercalated nonlipid-related mechanisms, such as inflammation and coagulation, impair the ability of genetic studies to implicate a direct role for triglycerides on ASCVD risk. One potential mechanism seems largely driven by the cholesterol carried within triglyceride-rich lipoproteins and their remnants, rather than their triglyceride content.

show abstract

Section: Atherosclerosis and Hypertriglyceridemiamentioning

confidence: 99%

Genetics of hypertriglyceridemia and atherosclerosis

Gill

Dron

Hegele

2021

Current Opinion in Cardiology

View full text Add to dashboard Cite

show abstract

“…Alterations in platelet function, including platelet hyperaggregability and hyperactivation is commonly seen in people with metabolic syndrome and contributes fundamentally to the increased risk of atherothrombotic diseases [37,38]. Oxidative stress plays a critical role in platelet hyperactivity, with platelet activation driven by ROS present both in the vasculature and generated by platelets themselves.…”

Section: Discussionmentioning

confidence: 99%

Ergothioneine supplementation in people with metabolic syndrome (ErgMS): protocol for a randomised, double-blind, placebo-controlled pilot study

Tian

Cioccoloni

Naseem

et al. 2021

Pilot Feasibility Stud

View full text Add to dashboard Cite

Background Ergothioneine is a naturally occurring metabolite of histidine found in many foods and in high amounts in mushrooms. In vivo, ergothioneine acts as an antioxidant and is widely distributed in most mammalian tissues. While ergothioneine is sold as a dietary supplement for its antioxidant and anti-inflammatory properties, to date there are no published intervention trials examining its health benefits in humans. The aim of this work was to develop a study protocol for a pilot interventional trial that will establish the primary and secondary outcomes, and the power required, for a definitive randomised controlled trial to test the hypothesis that ergothioneine supplementation is beneficial for people with metabolic syndrome. Methods We have designed the ErgMS study as a single-centre, randomised, double-blind, placebo-controlled, 3-arm parallel, pilot intervention trial, which aims to supplement participants with either placebo, 5 or 30 mg/day ergothioneine for 12 weeks. Measurements of metabolic syndrome risk factors, serum markers of oxidative stress (lipid peroxidation), inflammation, blood platelet function and liver function will take place at baseline, and after 6 weeks and 12 weeks of supplementation. In addition, we will examine if there are any changes in the serum metabolome in response to ergothioneine supplementation. Linear regression and two-way ANOVA will be utilised to analyse the association between ergothioneine and measured variables. Discussion The ErgMS study will be the first study to address the question does ergothioneine supplementation have health benefits for people with metabolic syndrome. Study results will provide preliminary data as to which dose may improve inflammatory markers in adults with metabolic syndrome and will inform dose and primary outcome selection for a definitive randomised controlled trial. Trial registration ISRCTN, ISRCTN25890011 Registered February 10th, 2021

show abstract

“…Moreover, the levels of albumin and protein C were lower in patients with liver cirrhosis compared to healthy controls, and low levels of albumin and protein C were associated with the increased risk of PVT formation ( 99 , 100 ). Abnormal metabolic state, hemodynamic changes, and PAI-1 in patients with NAFLD may contribute to prethrombotic state and hypercoagulable state ( 101 , 102 ). In a cross-sectional study, NASH-related cirrhosis was the strongest independent risk factor for the independent diagnosis of PVT in patients undergoing liver transplantation ( 103 ).…”

Section: Liver Cirrhosis-related Complications and Dysbiosismentioning

confidence: 99%

Liver cirrhosis and complications from the perspective of dysbiosis

Nie,

Zhang,

Xie

et al. 2024

Front. Med.

View full text Add to dashboard Cite

The gut-liver axis refers to the intimate relationship and rigorous interaction between the gut and the liver. The intestinal barrier’s integrity is critical for maintaining liver homeostasis. The liver operates as a second firewall in this interaction, limiting the movement of potentially dangerous compounds from the gut and, as a result, contributing in barrier management. An increasing amount of evidence shows that increased intestinal permeability and subsequent bacterial translocation play a role in liver damage development. The major pathogenic causes in cirrhotic individuals include poor intestinal permeability, nutrition, and intestinal flora dysbiosis. Portal hypertension promotes intestinal permeability and bacterial translocation in advanced liver disease, increasing liver damage. Bacterial dysbiosis is closely related to the development of cirrhosis and its related complications. This article describes the potential mechanisms of dysbiosis in liver cirrhosis and related complications, such as spontaneous bacterial peritonitis, hepatorenal syndrome, portal vein thrombosis, hepatic encephalopathy, and hepatocellular carcinoma, using dysbiosis of the intestinal flora as an entry point.

show abstract

Hypertriglyceridemia is associated with platelet hyperactivation in metabolic syndrome patients

Cited by 10 publications

References 48 publications

Genetics of hypertriglyceridemia and atherosclerosis

Genetics of hypertriglyceridemia and atherosclerosis

Ergothioneine supplementation in people with metabolic syndrome (ErgMS): protocol for a randomised, double-blind, placebo-controlled pilot study

Liver cirrhosis and complications from the perspective of dysbiosis

Contact Info

Product

Resources

About